Protective Humoral Immunity Elicited by a Needle-Free Malaria Vaccine Comprised of a Chimeric Plasmodium falciparum Circumsporozoite Protein and a Toll-Like Receptor 5 Agonist, Flagellin

Imaging murine NALT following intranasal immunization with flagellin-modified circumsporozoite protein malaria vaccines

(2013) A Nacer et al.   Mucosal Immunology

Evaluation of the Effectiveness and Safety of Chitosan Derivatives as Adjuvants for Intranasal Vaccines

(2013) Takashi Kobayashi et al.   VIRAL IMMUNOLOGY

A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Sporozoite neutralizing antibodies elicited in mice and rhesus macaques immunized with a Plasmodium falciparum repeat peptide conjugated to meningococcal outer membrane protein complex

(2012) Craig Przysiecki et al.   Frontiers in Cellular and Infection Microbiology

The Nasal Dendritic Cell-Targeting Flt3 Ligand as a Safe Adjuvant Elicits Effective Protection against Fatal Pneumococcal Pneumonia

(2011) Kosuke Kataoka et al.   INFECTION AND IMMUNITY

Immunological mechanisms of vaccination

(2011) Bali Pulendran et al.   NATURE IMMUNOLOGY

First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza–flagellin fusion vaccine (VAX125, STF2.HA1 SI)

(2011) David N. Taylor et al.   VACCINE

A Research Agenda to Underpin Malaria Eradication

(2011) Pedro L. Alonso et al.   PLOS MEDICINE

TLR5 or NLRC4 is necessary and sufficient for promotion of humoral immunity by flagellin

(2010) Matam Vijay-Kumar et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Vaccine Adjuvants: Putting Innate Immunity to Work

(2010) Robert L. Coffman et al.   IMMUNITY

Flagellin as an Adjuvant: Cellular Mechanisms and Potential

(2010) S. B. Mizel et al.   JOURNAL OF IMMUNOLOGY

Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study

(2010) Santtu Heinonen et al.   LANCET INFECTIOUS DISEASES

Immunopotentiation of Trivalent Influenza Vaccine When Given with VAX102, a Recombinant Influenza M2e Vaccine Fused to the TLR5 Ligand Flagellin

(2010) H. Keipp Talbot et al.   PLoS One

Safety and immunogenicity of a recombinant hemagglutinin influenza–flagellin fusion vaccine (VAX125) in healthy young adults

(2010) John J. Treanor et al.   VACCINE

Direct Stimulation of tlr5+/+ CD11c+ Cells Is Necessary for the Adjuvant Activity of Flagellin

(2009) J. T. Bates et al.   JOURNAL OF IMMUNOLOGY

Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection

(2009) Kent E. Kester et al.   JOURNAL OF INFECTIOUS DISEASES

Randomized Controlled Trial of RTS,S/AS02D and RTS,S/AS01E Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children

(2009) Seth Owusu-Agyei et al.   PLoS One

Enhanced Immunogenicity of Plasmodium falciparum Peptide Vaccines Using a Topical Adjuvant Containing a Potent Synthetic Toll-Like Receptor 7 Agonist, Imiquimod

(2008) C. Othoro et al.   INFECTION AND IMMUNITY

New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin

(2008) Daniel Y. Bargieri et al.   VACCINE

Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin

(2007) James W. Huleatt et al.   VACCINE